A $20 Billion Sale Price Tells You Why J&J Is Ditching Orthopedics

Apollo Global Management is in talks to buy the part of Johnson & Johnson most people don't think about — the artificial hip and knee business — and reports value it at close to $20 billion. J&J's stock ticked up after hours, which for a company worth roughly $640 billion is about 3% of the whole. You already know what I'm going to say: a move that small is the market telling you nothing new happened. The deal has been telegraphed for nearly a year. The real information isn't the money handshake, it's the price per dollar of revenue — and that number is the whole story.

Say what you want, but jettisoning the "world's largest, most comprehensive orthopaedics-focused company," in J&J's own billing, for about two times its annual sales is not the signature of a prized asset. The orthopedics business — it'll be called DePuy Synthes once it's on its own — booked about $9.3 billion of revenue last year, roughly a tenth of everything J&J sells. A purchase price "close to $20 billion" works out to a little over two times that revenue. Bloomberg Intelligence's estimate of $28 billion, counting the debt the business would carry, still lands it near three times sales. Either way you cut it, this is the multiple of a mature, slow-growing, encumbered business — not the funded-multiple of a growth engine.

That discount is the point, and it explains the entire separation.

J&J didn't wake up in October and decide orthopedics was dead weight. It had watched the unit grind through years of hip-replacement litigation and growth that trailed the rest of its medtech portfolio, then looked at the pile it calls "higher-growth, higher-margin markets" — oncology, immunology, neuroscience, cardiology, surgery, vision — and did the arithmetic. A division that needs constant defense against lawsuits and can only grow in the low single digits drags the sum-of-the-parts higher if it's kept, but it doesn't deserve a premium multiple if it's sold. So you sell it, and you pocket what the market's actually willing to pay.

Here's the sharper trade-off for anyone holding J&J, and it's the part this headline skips. J&J's CFO spelled out that the preferred path had been a tax-free spinoff — hand the business to shareholders as a new public company and no one pays tax on the exit. A sale is not that. Selling to Apollo means taking cash (and perhaps some equity) and giving up the tax efficiency, a real decision to trade the cleanest exit for certainty and speed. That's a concession, not a victory lap: better a cash price you can bank on than a spinoff whose price the market sets whenever it feels like it — and whose own lagging growth and litigation would follow it down the road anyway.

None of this is done. An agreement could come within weeks, or the talks could collapse, another bidder could step up, or J&J could fall back on spinning the business off publicly. The company still says separation is on track for mid-2027. Which outcome lands matters to J&J shareholders, because it decides the form of the proceeds: cash in hand from a sale, or continued ownership of a public DePuy Synthes in a spinoff.

And that's the thing to hold onto, because memory of the muted after-hours tick will fade. What won't: a company valued at $640 billion just told you how little the "world's largest orthopedics company" is worth on the open market, and it's walking away from it at roughly two times sales to get back to the businesses that deserve better multiples. If Apollo walks and nobody else shows up, the "$20 billion" is a floor, not a price. For a J&J holder, that's not a sell signal — it's a confirmation of what the portfolio's whole pivot has always been about.